바이오스펙테이터

바이오스펙테이터 Sungmin Kim 기자

“So far, many scientists had tried to discover new therapies for Alzheimer’s disease (AD), but failed to push their work because they were unable to fundamentally improve the microenvironment surrounding neurons,” Kim Bong-cheol, CEO of Neuracle Science, commented.

He elaborated: “The development of immunotherapy that stimulates immune cells in the tumor microenvironment (TME) has entirely changed the paradigm for cancer treatment. Like TME, brain diseases and their surrounding microenvironment are newly emerging as important and pharmacological targets in neurodegenerative diseases. We are now exploiting a promising strategy to control neuro-inflammation by manipulating glial scarring. Neuro-inflammation has been proposed as a target of amyloid beta.”

CEO Kim Bong-cheol emphasized that “Neuracle Science has taken different approaches to treat a wide array of neurodegenerative diseases by focusing on the microenvironment surrounding neurons.”

Typically, neuro-inflammation is a common pathology at the early stage of neurodegenerative diseases. It is becoming increasingly important because it contributes to disease progression. Proper neuro-inflammatory response is needed to promote repair process for damaged nerve function associated with excessive inflammation.... <계속>